Ftse Mib
33.294,96
0,00%
DAX
19.146,17
0,76%
S&P 500
5.948,71
0,53%
NASDAQ
18.972,42
0,03%
Bitcoin
99.094,02
0,59%
Pepperstone
Advertisement
Registration Strip Icon for monitor Monitora più quotazioni in tempo reale dalle principali borse, come Borsa Italiana, NASDAQ, NYSE, AMEX, Bovespa e altro ancora.
Registrati

Quotazioni in diretta

Non abbiamo trovato risultati per:
Assicurati di aver scritto correttamente o prova ad allargare la ricerca.

Più Attivi

Toplist

Sembra che tu non sia connesso.
Clicca il pulsante qui sotto per accedere e visualizzare la tua cronologia recente.

Registrati

Sei già registrato? Accedi

Pepperstone

Inizia Ora

Pepperstone
Home Investire Azioni U.S.A. NASDAQ HUTCHMED China Limited (HCM) HUTCHMED China Limited (HCM) Notizie

HUTCHMED China Limited

HCM
17,68
-0,28 (-1,56%)
22 Nov 2024 - Chiuso
Dati in Delay di 15 minuti
Borsa: NASDAQ
Tipo: Ricevuta di Deposito
Valuta: USD

Ultime notizie

Data Ora Fonte Titolo
22/11/202405:30GLOBEHUTCHMED Announces Launch by Takeda of FRUZAQLA®..
20/11/202412:03EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
20/11/202410:30GLOBEHUTCHMED Announces Appointment of Independent Non-executive..
06/11/202405:00GLOBEHUTCHMED Highlights Clinical Data to be Presented at the..
31/10/202409:30GLOBEHUTCHMED to Receive First Commercial Milestone Payment..
16/10/202406:30GLOBEHUTCHMED Announces that TAGRISSO® plus ORPATHYS®..
26/9/202414:51GLOBEDeutsche Bank ADR Virtual Investor Conference: Presentations..
24/9/202412:09EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
24/9/202409:00GLOBEHUTCHMED Announces Japan Approval for FRUZAQLA®..
17/9/202417:22GLOBEInternational companies to host live webcasts at Deutsche..
09/9/202402:00GLOBEHUTCHMED Highlights Clinical Data to be Presented at ESMO..
30/8/202412:13EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
30/8/202406:30GLOBEHUTCHMED Provides Update on Fruquintinib for Second-Line..
22/8/202412:10EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
21/8/202412:07EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
21/8/202410:30GLOBEHUTCHMED to Host Expert Call to discuss Immune..
31/7/202413:13EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
31/7/202413:00GLOBEHUTCHMED Reports 2024 Interim Results and Provides..
04/7/202402:00GLOBEHUTCHMED Announces NDA Acceptance in China for Tazemetostat..
26/6/202410:30GLOBEHUTCHMED to Announce 2024 Half-Year Financial Results
24/6/202411:30GLOBESave the Date: HUTCHMED to Present R&D Updates on July 9,..
21/6/202422:00GLOBEHUTCHMED Announces European Commission Approval for..
17/6/202402:00GLOBEHUTCHMED Highlights Publication of Phase III ESLIM-01..
07/6/202412:25EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
07/6/202402:00GLOBEHUTCHMED Initiates Phase I Trial of Menin Inhibitor HMPL-506..
03/6/202412:13EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
03/6/202402:00GLOBEHUTCHMED Highlights Publication of Phase III FRUTIGA Results..
31/5/202412:12EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
24/5/202412:06EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
24/5/202402:00GLOBEHUTCHMED Highlights Presentations at the 2024 ASCO Annual..
17/5/202416:02EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
17/5/202416:00GLOBEHUTCHMED announces retirement of Chairman, appointment of..
17/5/202402:00GLOBEHUTCHMED Highlights Sovleplenib Phase III ESLIM-01 Study and..
14/5/202402:00GLOBEHUTCHMED Initiates the RAPHAEL Registrational Phase III..
08/5/202410:30GLOBEHUTCHMED Announces Appointment of Independent Non-executive..
26/4/202414:30GLOBEHUTCHMED Announces Positive CHMP Opinion for Fruquintinib in..
05/4/202410:30GLOBEHUTCHMED Highlights Data to be Presented at..
02/4/202406:30GLOBEHUTCHMED and Innovent Jointly Announce NDA Acceptance in..
28/3/202401:00GLOBEHUTCHMED Announces Savolitinib sNDA Accepted in China for..
22/3/202401:00GLOBEHUTCHMED Initiates Registration Stage of the ESLIM-02 Phase..
05/3/202412:04EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
28/2/202412:47EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
28/2/202412:40EDGAR2Form 20-F - Annual and transition report of foreign private..
28/2/202412:30GLOBEHUTCHMED Reports 2023 Full Year Results and Provides..
07/2/202412:43EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
07/2/202401:00GLOBEHUTCHMED Highlights Presentation of Phase III Data on..
02/2/202412:15EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
02/2/202409:30GLOBEHUTCHMED Announces that Inmagene Exercises Option to License..
01/2/202412:06EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
01/2/202409:30GLOBEHUTCHMED to Announce 2023 Final Results
Apertura: 17,81 Min: 17,52 Max: 17,81
Chiusura: 17,96

La tua Cronologia

NASDAQ
HCM
HUTCHMED China
Delayed Upgrade Clock

Il sito ADVFN Italia è stato realizzato ed è gestito da PRODESFIN su licenza di ADVFN PLC.

PER CONTATTI E PUBBLICITA' SUL SITO CLICCARE QUI

Accedendo ai servizi offerti da ADVFN, ne si accettano le condizioni generali Termini & Condizioni

ADVFN Network